MSI2 is an RNA-binding protein that regulates target mRNA expression at the translational level 1. In hematopoietic stem cells (HSCs), MSI2 maintains primitive cell fate by balancing self-renewal and differentiation, partly through Notch signaling regulation 2. MSI2 stabilizes specific mRNAs, including c-Myc and BCAT1, through recognition of N6-methyladenosine modifications 13. Genetically, a protective regulatory variant (rs17834140-T) that down-regulates MSI2 in HSCs confers resilience against clonal hematopoiesis and myeloid malignancies 4. Clinically, MSI2 overexpression is associated with poor prognosis across multiple malignancies, correlating with unfavorable overall survival (HR=1.85) and disease-free survival (HR=2.19) 5. MSI2 drives therapy resistance in gastric cancer through c-Myc stabilization 1 and in B-cell lymphoma through synergy with PRMT5 activity 6. Beyond cancer, MSI2 overexpression enhances muscle dysfunction in myotonic dystrophy type 1 through an autophagy axis 7. Genetic evidence links MSI2 variants to schizophrenia susceptibility, suggesting roles in neurogenesis 8. MSI2 inhibition represents a rational therapeutic strategy for preventing blood cancer progression and reversing chemoresistance.